Skip to content
Next results · Q4 2026Projected

Feb 25, after the close

Thu, Feb 25, 2027in 100 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 24 – Mar 5

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$75.45M
Revenue, change from a year earlier: Q3 2026 +1.1%, Q2 2026 +7.8%, Q1 2026 −2.6%, Q4 2025 +27.7%
Net income
$13.44M
Net income, change from a year earlier: Q3 2026 −32.7%, Q2 2026 +39.9%, Q1 2026 n/m, Q4 2025 −30.4%
EPS
—
EPS, change from a year earlier: Q3 2026 −35.3%, Q2 2026 +33.3%, Q1 2026 n/m, Q3 2025 −58.5%

Results day

Typical moveA typical move of 10.8% either way

Up after 8 of 12, down after 4.

The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: −24.9% after Q4 2025.

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

When it reports

Usual day
Thursday
8 of its last 8
Session
after the close
After quarter end
37 to 57 days
10-Q filed
37 to 38 days
over its last 8
10-K filed
58 to 61 days
over its last 8

Based on 8 prior 10-K filings.

Puma Biotechnology, Inc. · CIK 1401667 · Engraved from SEC EDGAR